Advanced search
Start date
Betweenand

Analysis of complementary parameters based on the immune profile for prognosis of dogs with cutaneous mastocytoma

Grant number: 19/12107-0
Support type:Scholarships in Brazil - Scientific Initiation
Effective date (Start): September 01, 2019
Effective date (End): August 31, 2020
Field of knowledge:Agronomical Sciences - Veterinary Medicine
Principal Investigator:Cristina de Oliveira Massoco Salles Gomes
Grantee:Paula Kawamura Bernardi
Home Institution: Faculdade de Medicina Veterinária e Zootecnia (FMVZ). Universidade de São Paulo (USP). São Paulo , SP, Brazil

Abstract

Canine mastocytoma is a neoplasm of high incidence and high malignancy. Currently, the search for new prognostic factors and treatment modalities for this neoplasm is increasing. A possible prognostic and predictive tool would be the use of hematological indices (NRL, PLR, MLR and SII) - obtained through blood markers present in hemograms - to compose the immune profile of patients with mastocytoma, in order to provide more information about each specific case, also assisting in the follow-up and choice of treatment. The study consists of collecting retrospective data from the HOVET FMVZ-USP surgery service of 120 canine patients with malignant mastocytoma that will be divided into three groups according to their treatment: GC = surgery; GQ = chemotherapy and GCQ = surgery associated with chemotherapy. To characterize the immune profile of each patient the values of neutrophils, lymphocytes, platelets and monocytes will be considered. They will be obtained from the hemogram, which blood was collected in the following moments: moment of diagnosis (MD), 30 days after treatment (D30) and 60 days after treatment (D60). The indices will be calculated and submitted to univariate statistical analysis, with a 95% confidence interval. Thus, it is expected that the results obtained demonstrate a relationship between the hematological indices and the survival of the patients studied, in order to demonstrate the possibility of a new prognostic and predictive tool of low cost for dogs with cutaneous mastocytoma.